Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis

Numnum TM, Kimball KJ, Rocconi RP, Kilgore LC, Straughn JM Jr. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:1019–1024. The objective is to assess the cost-effectiveness of pegfilgrast...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of gynecological cancer 2007-09, Vol.17 (5), p.1019-1024
Hauptverfasser:	Numnum, T.M., Kimball, K.J., Rocconi, R.P., Kilgore, L.C., Straughn, J.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Bridged-Ring Compounds - adverse effects Bridged-Ring Compounds - therapeutic use Carcinoma - drug therapy Chemotherapy Cohort Studies Cost analysis Cost-Benefit Analysis cost-effectiveness analysis Disease prevention Female Filgrastim Granulocyte Colony-Stimulating Factor - economics Granulocyte Colony-Stimulating Factor - therapeutic use granulocyte-colony stimulating factor Hospitalization Hospitalization - economics Humans Neutropenia Neutropenia - etiology Neutropenia - prevention & control Ovarian cancer Ovarian Neoplasms - drug therapy Ovaries Patients pegfilgrastim Polyethylene Glycols Recombinant Proteins Taxoids - adverse effects Taxoids - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!